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Abstract 
Novel analytical study was performed in order to develop and validate new high-throughput microwell-based 
spectrophotometric assays for determination of omeprazole (OMZ) in its pharmaceutical formulations. The proposed 
assays were based on the charge-transfer (CT) reaction of OMZ with 2,3-dichloronaphthoquinone (DCNQ) and 2,3,5,6-
tetrabromo-1,4-benzo-quinone (BROM). In the present study, the CT reactions was carried out in microwell plates as 
reaction vessels in order to increase the automation of the assays and the efficiency of its use in quality control 
laboratories (QCLs). All factors affecting the CT reactions were carefully studied, and the conditions were optimized. 
Kinetics and stoichiometry of the CT reactions were investigated, and the mechanism was postulated. Activation energy of 
the CT reactions was determined and found to be 13.87 and 16.27 Kcal mol−1 for the reaction of OMZ with DCNQ and 
BROM, respectively. The initial rate and fixed time methods were applied for generating the calibration graphs for 
determination of OMZ concentrations. Under the optimum conditions, the linear range was 0.145 – 1.45 x 10-4 and 1.45 – 
7.25 x 10-4 M with LOD of 0.6 and 6.0 g ml-1 for DCNQ and BROM, respectively. Analytical performance of the proposed 
methods, in terms of accuracy and precision, was statistically validated and the results were satisfactory; RSD was <2.8% 
for both repeatability and reproducibility. The proposed methods were successfully applied to the analysis of OMZ in its 
dosage forms and the recovery results (98.64 – 100.6  0.25 -2.74 %) were comparable with those of the reported 
method. The developed method may provide a safer and economic tool for the analysis of OMZ in QCLs.  
Keywords: Omeprazole; 2,3-dichloronaphthoquinone; bromanil; Charge-transfer complexes; Kinetics. 
1.  Introduction 
Omeprazole (OMZ) is a selective and irreversible proton pump inhibitor. It blocks the stomach acid release via 
specific inhibition of the H+/K+-ATPase enzyme system present at the secretory surface of gastric parietal cells.  
Omeprazole is listed in the WHO's list of essential medicines, the most effective and safe medicines needed in a health 
system.  Therefore, OMZ is widely used for treatment of peptic ulcers, gastroesophageal reflux, and Zollinger–Ellison 
syndrome [1-2]. Recently, OMZ has been used as a potential anti-inflammatory agent [3] to protect the gastric mucosa 
from the inflammation caused by Helicobacter pylori infection (in a triple therapy combination with amoxicillin, 
and clarithromycin) or by long-term therapy with aspirin and non-steroidal anti-inflammatory agents. This therapeutic 
importance of OMZ was behind the growing interest in the development of many analytical methods for its determination in 
the pharmaceutical formulations and/ or biological samples. Omeprazole is a lipophilic base with pKa1=4.2 and pKa2= 9.0.   
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Literature survey showed that several techniques have been reported for assay of OMZ in pharmaceutical 
preparations or biological fluids. The reported techniques are liquid chromatography with either UV [4-9] or Mass 
spectrometric [10-12] detection, electrophoresis [13, 14], electrochemistry [15, 16], fluorimetry [17-19] and 
spectrophotometry [2, 20-25]. The sophisticated instrumentation, high analysis cost and long time required to obtain the 
most suitable conditions limit the routine use of the separation-based techniques in quality control laboratories (QCLs) 
where higher sensitivity is not required. Among these techniques, spectrophotometry stands out, as the most effective and 
convenient analytical technique as compared to the others with respect to simplicity, cost, and wide availability in most 
QCLs. However, matrix interference disadvantage the direct UV spectrophotometric analysis of OMZ [3]. In addition, other 
interferences resulting from non-selective oxidation of OMZ may affect some reported methods [20]. Today, Kinetic 
spectrophotometric methods have gained great interest in the area of pharmaceutical analysis. Kinetic methods can 
improve the selectivity owing to the possible avoiding of the matrix interferences in the commercial products if they can 
withstand the reaction conditions established for the proposed kinetic method [26]. 
Nowadays, molecular charge–transfer (CT) reactions have been widely used in different areas of pharmaceutical and 
medical sciences. The importance and widespread of CT reactions are attributed to their presence in many biological 
systems [27], their use in studying the thermodynamics and pharmacodynamics of medical substances [28], and in 
explaining how the drugs and the receptors interact [29]. In the area of pharmaceutical analysis, their great importance 
comes from the rapid formation of intensely colored CT complexes characterized by new absorption band of longer 
λmax than that of their components [30]. The higher λmax of the new band is a decisive advantage since the interference 
from the associated ingredients shall be far less at higher wavelengths. The formation of new absorption bands in CT 
reactions resulted in development of many spectrophotometric assays for pharmaceutical compounds [31-33]. CT 
reactions were reported for OMZ using both iodine as σ-acceptors [25] and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ) [19, 25], 7,7',8,8'-tetracyanoquinodimethane (TCNQ) [32]  and p-chloranilic acid [33] as π-acceptors. Yet, no 
attempt has been carried out for using both 2,3-dichloronaphthoquinone (DCNQ) and 2,3,5,6-tetrabromo-1,4-
benzoquinone (BROM) reagents for CT complexation of OMZ.  The use of micro-well plates as reaction vessels instead of 
normal volumetric flasks can reduce both consumption and cost of organic solvents, and decrease the risk of human 
exposure to toxic solvents [19]. 
These facts promoted our interest in utilizing DCNQ and BROM reagents for developing novel, simple and low-cost 
kinetic spectrophotometric methods for the determination of OMZ in QCLs.    
2.  Experimental  
2.1. Apparatus  
A Shimadzu model UV-1601 PC (Japan) UV-VIS double beam spectrophotometer with matched 1-cm quartz cells 
was used for recording the electronic absorption spectra. BioTek ELx 808 ELISA reader (BioTek, USA) was used for all 
measurements. UltraCruz® polypropylene microplates, 96 well with U bottom (were obtained from Santa Cruz 
Biotechnology, Inc. (USA). Finn pipette adjustable 8 channel-pipettes were purchased from Sigma Chemical Co., USA. 
2.2. Chemicals and reagents 
OMZ (Hetero Drugs Ltd, Hyderabad, India) was used as working standard. 2,3,5,6-Tetrabromo-1,4-benzoquinone 
(bromanil; BROM, Hopkin & Williams Ltd, UK) was 2.36x10-3 M (0.1%)  in acetonitrile. 2,3-Dichloro-naphthoquinone 
(DCNQ; Merck, Schuchardt, Munich, Germany) was 3.52x10-3 M (0.08%) in acetonitrile.  BROM and DCNQ solutions 
were freshly prepared daily.  All solvents and other chemicals used throughout this study were of analytical grade. 
2.3. Pharmaceutical formulations 
Gastrazole capsules (Riyadh Pharma, Saudi Arabia) and Losec tablets (AstraZeneca, Sweden) were labeled to 
contain 20mg OMZ per capsule or tablet.  
2.4. Preparation of standard and sample solutions  
2.4.1. Preparation of stock standard solution 
One hundred twenty five mg of OMZ was accurately weighed, transferred into a 50-ml calibrated flask, dissolved in 20 
ml acetonitrile, and completed to volume with the same solvent to obtain a stock solution of 2.5 mg.ml-1. This stock 
solution was further diluted with acetonitrile to obtain suitable concentrations that lie in the linear range of each particular 
assay method.  
2.4.2. Preparation of tablets or capsules solution 
Twenty tablets or the contents of twenty capsules of each formulation were finely powdered and/or weighed. A 
quantity of the powder equivalent to 75 mg of OMZ was transferred into a 25-ml calibrated flask, dissolved in 20 ml of 
acetonitrile, swirled and sonicated for 5 min. The flask content was completed to volume with acetonitrile, shaken well for 
15 min and filtered. The first portion of the filtrate was rejected and a measured volume of the filtrate was diluted 
quantitatively with acetonitrile to yield suitable concentrations that lie in the linear range of each particular assay method.  
2.5. General analytical procedure 
2.5.1. Initial rate method 
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Hundred microliters of the standard or sample solution of OMZ (12.0 – 500.0 g ml-1) was transferred into the wells of 96-
microwell plate. Hundred microliters of DCNQ (3.52x10-3 M) or BROM (2.36x10-3 M) solution was added to each well. 
ELISA microplate reader measured the absorbance of the resulting solutions at 416 and 490 nm for DCNQ and BROM, 
respectively. The CT reaction was monitored at 45 ± 2 °C and the absorbance was recorded as a function of time each 5 
min for 40 and 25 min for DCNQ and BROM, respectively. Blank wells were treated similarly using 100 μl of acetonitrile 
instead of OMZ. The absorbance of blank wells were subtracted from those of standard or sample wells.   
2.5.2. Fixed time method 
Hundred microliters of the standard or sample solution of OMZ (12.0 – 500.0 g ml-1) was transferred into the wells of 96-
microwell plate. Hundred microliters of DCNQ (3.52x10-3 M) or BROM (2.36x10-3 M) solution was added to each well. The 
CT reaction was allowed to proceed at 45 ± 2 °C for 40 and 25 min for DCNQ and BROM, respectively. ELISA microplate 
reader measured the absorbance of the resulting solutions at 416 and 490 nm for DCNQ and BROM, respectively. Blank 
wells were treated similarly using 100 μl of acetonitrile instead of OMZ. The absorbance of blank wells were subtracted 
from those of standard or sample wells. 
2.6. Association constant and free energy change                     
Series of OMZ solutions (410-5 - 6 10-2 M) in acetonitrile were prepared. These solutions and DCNQ (3.6 10-3 M) 
and BROM (2.4 10-3 M) solutions in acetonitrile were equilibrated for 30 min in a thermostatically controlled water bath at 
452 
o
C.  Five milliliters of each acceptor solution was mixed rapidly with 5 ml of OMZ solution in 10-ml calibrated flasks.  
The absorbance of the solutions was measured immediately at the corresponding maxima against reagent blanks treated 
similarly. 
2.7. Molecular modeling for the CT complexes                     
Molecular modeling for the CT complexes were carried out using the MOPAC package in the CHEM 3D Ultra, 
version 9.0 (ChemOffice software, CambridgeSoft Corporation, Cambridge, MA, USA) implemented with molecular 
dynamics computations software (MM2).  OMZ and the acceptor (bromanil as representative examples) were energy-
minimized alone and both together to obtain the most energy-minimized conformation of OMZ CT complexes. 
Furthermore, the total charges on all nitrogen atoms were calculated. 
2.8. Validation of the proposed methods 
The following validation parameters were assessed and evaluated according to ICH guidelines [34]. The standard curve 
for determination of OMZ was constructed by plotting the color intensities obtained by using the general procedures of the 
proposed methods as a function of the corresponding concentrations. The least squares method was used for getting the 
regression equation. The limits of detection (LOD) and limits of quantitation (LOQ) were determined [34] using the formula: 
LOD or LOQ = .SDa/b, where  = 3.3 for LOD and 10 for LOQ, SDa is the standard deviation of the intercept, and b is 
the slope (sensitivity) of the proposed method. Intra- and inter-day accuracy and precision of the proposed method were 
assessed by recovery studies at three (low, medium and high) concentration levels. Recovery was determined by the 
standard addition method. Known amounts of OMZ were added to the pre-determined drug-containing dosage forms, and 
then determined by the proposed methods. The mean recovery was determined by dividing the measured concentrations 
to the concentrations taken for analysis, expressed in percentages. The intra-day precision and accuracy were determined 
by carrying out the assay of six replicate samples of each concentration as one batch in a single run, while the inter-day 
precision and accuracy were determined by repeating the assays for the same samples at three different days. The 
selectivity of the proposed method was studied by testing the interferences liability from the excipients of the dosage 
forms.  Common excipients such as starch, glucose, lactose, acacia, and magnesium stearate were used in this study. 
The recovery was calculated each time.  Ruggedness was also tested by two different analysts at two different elapsed 
times. Moreover, robustness was evaluated at small variation in the -acceptor concentration, reaction temperature and 
reaction time  
3.  Results and discussion 
3.1. Spectral characteristics of the formed complexes, design and strategy for the assay 
development  
OMZ has an absorption spectrum in the UV range of 200-340 nm with maximum absorption at 278 and 298 nm. 
However, it has no considerable absorption band in the visible range of 400–600 nm. Addition of OMZ to both 
polycyanoquinone (DCNQ) and polyhaloquinone (bromanil) -acceptors in polar solvents such as acetonitrile or methanol 
resulted in colored CT complexes characterized by considerable absorption bands in the visible range of 400–600 nm with 
high ε-values. This was attributed to complete electron transfer from OMZ to the -acceptor moiety (A) accompanied by 
the formation of colored radical ions [30], according to Scheme I. The high ionizing power of the polar solvent is the driving 
force for dissociation of the (OMZ-A) CT complex to form the colored radical ion. Spectral features of OMZ CT complexes 
with the studied -acceptors were similar to those observed for their interaction with other donors [29, 35-36], and the 
reported values of the radical anions of these acceptors obtained by the iodide reduction method [36]. As shown in Figure 
1.  
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Figure 1.  
Absorption spectra of OMZ (50 g ml-1, 1) and its reaction products with DCNQ (1.76 x 10-2 M, 2), and BROM (1.18 x 10-2 
M, 3) in acetonitrile. Concentrations of OMZ were 50 and 100 g ml-1 for the reaction with DCNQ and BROM, respectively. 
           The OMZ-DCNQ complex exhibited two absorption bands at 416 and 496 nm (intensity of the 416 nm band is 
2.2fold more than the 496 nm band), while OMZ-BROM exhibited only one absorption band at 490 nm. The 
measurements of OMZ-DCNQ complex were carried out at 416 nm to increase the sensitivity of the assay. The interaction 
of OMZ with both DCNQ and BROM was found to be slow at room temperature (252
o
C). Therefore, they were carried out 
at elevated temperatures.  
 
 
  
 
Scheme I 
Our previous success in increasing the automation, economy and safety of the CT-reactions [19, 37] encouraged us to 
design a micro-well-based CT assays and measuring the signal with an ELISA reader.   
 
3.2. Optimization of the reaction conditions 
The factors influencing the reaction of OMZ with both DCNQ and BROM in the 96-microwell designed format and hence 
the color intensity (the reagent concentration, reaction time, reaction temperature, and the diluting solvent) were carefully 
studied by altering each variable in turn while keeping the others constant. 
3.2.1. Effect of temperature on the color intensity 
Preliminary experiments for studying the reaction of OMZ with both DCNQ and BROM -acceptors indicated very slow 
reaction for both studied acceptors with OMZ. Therefore, it seemed better to investigate the effect of temperature on the 
reaction of OMZ with both acceptor firstly through following up the color development at different temperatures using fixed 
concentrations of OMZ and the acceptors. Different temperatures: 25, 30, 35, 40, 45, 50, 60, 70 and 80 °C were tried to 
reach the optimum reaction temperature for OMZ with the investigated acceptors. The results showed that complete color 
development was reached at 45°C and becomes nearly stable until reached 70°C. However, higher temperatures than 
70°C was found to decrease the color intensity. In order to suit for measuring the absorbance using ELISA reader, a 
temperature of 45  2C was found to be the best choice for the investigated -acceptors (Figure 2). Therefore, further 
experiments were carried out at 45  2C. 
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Figure 2.  Effect of reagent concentration on the color intensity of the CTC of OMZ with DCNQ () and 
BROM () reagents in acetonitrile at 45±2°C. OMZ concentration was 55 and 200 g ml-1 for DCNQ and 
BROM, respectively. 
3.2.2. Effect of -acceptor concentration on the color intensity 
     The CT complex formation reaction was studied as a function of -acceptor concentration. The results indicated 
that 100 μl of DCNQ (0.08%) and BROM (0.1%) working solution were the optimum reagent concentrations, and higher 
blank readings with decreased absorbance intensities were obtained if higher amounts of -acceptors were used (Figure 
3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Effect of temperature on the color development of the CTC of OMZ with DCNQ (1.76 x 10-2 M ()) 
and BROM ((1.18 x 10-2 M ()) reagents in acetonitrile. OMZ concentration was 30 and 100 g ml-1 for DCNQ 
and BROM, respectively. 
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3.2.3. Effect of time on the color intensity 
       Since the colored complex formation increases with time, it was deemed useful to generate absorbance-time curve in 
order to determine the reaction kinetics and the optimum time for obtaining the highest absorbance intensity. This was 
performed by following up the color development at 45  2C using fixed amounts of OMZ and studied acceptors. The 
results revealed that complete color development was attained after 25 min and 40 min for BROM and DCNQ, 
respectively (Figure 4). The developed colors remained stable for at least a further 15 min, and then decreased. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  The absorbance-time curve for the reaction of OMZ at room temperature with: 
(A) DCNQ (1.76 x 10-2 M); the concentrations of OMZ were 2.910-5 (), 5.810-5 (), 8.6910-5 (∆), 
11.610-5 (), 14.510-5 (), and 17.410-5 M (), and 
(B) BROM (1.18 x 10-2 M); the concentrations of OMZ were 1.4510-4 (), 2.910-4 (), 4.3510-5 (∆), 
5.810-5 (), 7.2510-5 M () 
3.2.4. Effect of solvent on the color intensity 
  In order to select the most appropriate solvent, the reactions were carried out in different solvents. Small shifts in the 
position of the maximum absorption peaks were observed, and the absorption intensities were influenced. Acetonitrile was 
found to be an ideal solvent because it resulted in the highest sensitivity. This was attributed to its high dielectric constant 
that promotes the highest yield of radical anions, in addition to its high solvating power for the -acceptors [38].  
 The optimum conditions for obtaining the highest sensitivity for both -acceptors were summarized in Table 1.  
A 
B 
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Table 1: Optimum conditions for the charge-transfer reaction of OMZ with DCNQ and BROM at the 
specific λmax and reaction temperature. 
Kinetic parameters DCNQ method BROM method 
max (nm) 416 490 
Solvent Acetonitrile Acetonitrile 
Acceptor conc.  (%) 0.08 0.10 
Time (min) 40 25 
Temperature (C) 45 45 
 
The relative sensitivity of the investigated -acceptors employed in the present analytical study may be 
attributed to their difference in electron affinities, as well as the conditions employed in the reaction (-
acceptor concentration and reaction time).  
3.3. Conductivity studies 
In the present investigation, the resulting OMZ–acceptor reaction product in acetonitrile exhibited appreciable 
conductivities which may be due to the formation of CT complex. As a representative example, OMZ-DCNQ complex 
yielded a conductivity–mole fraction plot with maximum at OMZ: DCNQ molar ratio of 1:1 as indicated in Figure 5. 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5. 
Conductivity of OMZ-DCNQ complex vs. mole fraction of OMZ plot in acetonitrile at room temperature. 
           The increase in the observed conductivity upon complex formation is attributed to the ionization of the formed OMZ-
DCNQ complexes into radical ions in polar solvents giving rise to appreciable conductivity according to Scheme II [39]. 
The value of the conductivity above a base line connecting the conductivities of pure OMZ and DCNQ solutions is a 
measure of the excess conductivity caused by the formation and subsequent ionization of the CT complex. 
3.4. Molar ratio of the CT complex reaction and the proposed site of interaction  
Job’s method [40] was carried out using master equimolar solutions of OMZ and acceptors; (BROM; 1 10-3 M), and 
(DCNQ; 3 10-4 M) for determining the molar ratio of OMZ to each of BROM or DCNQ in the CT reactions. The results 
showed 1:1 ratio in both CT reactions confirming that OMZ has only one site for the reaction with each of BROM or 
DCNQ.  
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3.5. Molecular modeling and the suggested mechanism of the CT reaction  
The results of studies of both conductivity and Job’s method of continuous variation as well as the molecular modeling 
for OMZ-BROM complex confirmed that the reaction could occur only at the benzimidazole moiety of OMZ. (At the 
benzimidazole nitrogen in the para-position of OCH3-group since it has the highest electron density as compared to the 
other nitrogen atoms). Figure 6 shows the most energy-minimized conformation of OMZ-BROM complex.  
Figure 6. The most energy-minimized conformation of OMZ-BROM charge-transfer complexes. 
             
 
 
 
 
This is due to the fact that, the negative inductive effect of SO group decreases the charge densities (basicity) at the 
tertiary nitrogen atom.  Thus, the suggested mechanism for the CT OMZ - DCNQ reaction was postulated and assembled 
by the scheme shown in  
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Figure7.  A scheme for the charge-transfer reaction of OMZ with both (A) DCNQ and (B) BROM 
reagents. 
3.6. Kinetic studies for the formation of OMZ-DCNQ and OMZ-BROM complexes 
3.6.1. Order of the proposed CT reactions  
Under the described optimum conditions, the absorbance-time curves for the reaction of OMZ with both DCNQ and 
bromanil acceptors were constructed. Figure 4 shows the absorbance-time curves for the reaction of varying OMZ 
concentrations (0.29- 1.74 x 10-4 M) with fixed concentration of BROM (1.18 10-2 M) or DCNQ (1.76 10-2 M). The initial 
reaction rates (K) of the reactions were determined from the slopes tangents of these curves. Regression analysis was 
performed by plotting log K (at different OMZ concentrations) vs. log C by fitting the results to the following equation [35] 
Log K = log K + n log C 
A 
B 
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Where: K is the initial reaction rate, K is the rate constant, C is the molar concentration of OMZ, and n (slope) is the order 
of the reaction. The results obtained in Table 2 for both reactions confirmed that the both reactions were first order with 
respect to OMZ, where the value of (n) were 1.03 and 1.02 (≈ 1) for both BROM and DCNQ, respectively. 
Table 2: Kinetic parameters obtained from Benesi-Hildebrand, Arrhenius and first-order linear plots of 
OMZ CT complexes with DCNQ and BROM at the specific λmax and reaction temperature. 
Kinetic parameters DCNQ method BROM method 
Correlation coefficient (r) 0.9998 0.9991 
Order of CT reaction (n) 1.03 1.02 
Specific rate constant, sec-1 (k) x 104 5.63 4.53 
Activation energy, Kcal mol-1 (Ea)* 13.87 16.27 
Activation entropy change, Kcal mol-1 deg (∆So) -49.03 -48.90 
Molar absorptivity, l. mol-1 cm-1 (ε) x 103 2.82 1.34 
Standard free energy change, Kcal mol-1  (Go)♠ - 3.88 - 3.80 
Association constant, l.mol-1 (Kc) x 103 0.69 0.62 
♠ Negative sign of Go indicates endothermic reaction 
      However, under the optimized experimental conditions, both bromanil and DCNQ were used in relative excess amount 
as compared to OMZ in the reaction mixture. Thus, both reactions were considered as pseudo-first order reactions.  
3.6.2. Activation energy and entropy of activation of the CT complexes  
The activation energy, the minimum kinetic energy that a molecule must possess in order to undergo a reaction, can 
be determined from Arrhenius equation [41]: 
Log k   = log A – Ea / 2.303 RT 
Where: k is the apparent rate constant, A is a constant known as Arrhenius frequency factor, Ea is the activation energy, T 
is the absolute temperature (273+ °C), and R is the gas constant; 1.987 Calories deg-1 mole-1. This was done by 
generation of absorbance-time curves for each reaction at different temperatures; 25, 30, 35, 40, 45, 50, and 60 °C using 
fixed concentrations of OMZ and the acceptors. The values of Log K were plotted vs 1/T 
The activation energy of the reaction of OMZ with both acceptors determined from the slope; (– Ea / 2.303 R) of the 
straight lines were 13.87 and 16.27 Kcal mol-1 (Table 2) for both DCNQ and BROM, respectively.  These high activation 
energies obtained for both the investigated reactions explained that the reaction between OMZ and both acceptors was 
strongly dependent on the temperature and both acceptors could be used as useful reagents for determination of OMZ.  
Furthermore, the change in the entropy of activation of the transition state of the complexes was determined using the 
following equation [41]: 
A = (RT/Nh).e∆S*/R 
Where: A is the Arrhenius frequency factor, T is the absolute temperature, and R is the gas constant, N is Avogadro’s 
number (6.62 x 10-27 erg sec mole-1), h is Planck’s constant (6.02 x 1023 molecule mole-1) and ∆S* is the change in the 
entropy of activation (Cal mole-1 deg-1). The obtained large negative entropies of activation of the complexes (Table 2) 
support the formation of more polar transition state in the polar solvent 
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3.6.3. Association constant and standard free energy change of the CT complexes 
The association constant was evaluated at the corresponding λmax for each OMZ–acceptor complex using the 
Benesi–Hildebrand equation [42]:  
                             [A

]               1                 1                 1 
                                               =            +            
                             A
AD   
          
AD
           Kc
AD
. 
AD
       [D

]  
where [A

], the concentration of the acceptor; [D

], the concentration of the donor; A
AD
, the absorbance of the complex 
formed at the specific wavelength; 
AD
, the molar absorptivity of the complex formed at the specific wavelength; Kc
AD
; the 
association constant of the complex (l mol-1). On plotting the values [A

]/A
AD
 versus l/[D

], straight lines were obtained, 
from which the association constant, correlation coefficient and the molar absorptivity of OMZ–acceptor complexes were 
calculated (Table 2). The relative low values of the association constants of both BROM-OMZ and DCNQ-OMZ complexes 
(Table 2) may be attributed to the common feature of CT complexes with –acceptors and dissociation of OMZ–acceptors 
complexes to their radical anions. 
 
The standard free energy change of the complex is related to the association constant by the following equation [30]:  
∆G0 = - 2.303 RT log Kc 
where ∆G0 is the standard free energy change of the complex; R is the gas constant (1.987 cal mol-1 °C); T is the 
temperature in Kelvin degrees (273°C), and Kc is the association constant of OMZ-acceptor complex (l mol-1). OMZ 
formed complexes with very low association constant values (Table 2) with the investigated -acceptors due to the 
dissociation of the original donor–acceptor complex to the radical anion [30].  
 
3.7. Validation of the proposed kinetic methods 
In the present study, since the color formation of the CT complexes increases with time, it was utilized to elaborate 
kinetic-based methods for the determination of OMZ. Kinetic spectrophotometric methods are becoming of great interest in 
pharmaceutical analysis [26].  
 
3.7.1. Linearity and limits of detection 
3.7.1.1. Initial rate method 
Under the above described optimum conditions, summarized in Table 1, the initial rates of the CT reaction of OMZ 
with the acceptors would follow a pseudo-first order kinetic, and were found to obey the following equation:  
Log K = log K + n log C 
Regression analysis using the method of least square was performed to evaluate the slope, intercept and correlation 
coefficient. The analytical parameters and results of regression analysis are given in Table 3.   
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Table 3.  Analytical parameters for the initial rate method of the proposed kinetic spectrophotometric 
methods for determination of OMZ 
 
 
 
Method 
 
 
Linear range (M) 
Least square equation  
(Log V = log K’ + n 
log C) a 
 
 
Correlation 
coefficient        (r) 
 
 
LOD 
(M)         Intercept  
(log K’) 
Slope  
  (n) 
DCNQ 1.4510-5-1.4510-4 M 2.1993 
1.0230 0.9996 
0.17 x10-5 
M 
BROM 1.4510-4-7.2510-4 M 1.5140 
1.0220 0.9991 
1.7 x10-5 
M  
a V is the reaction rate, K’ is the conditional rate constant, n is the order of reaction, and C is the molar concentration of 
OMZ.  
        The limits of detection (LOD) were calculated and found to be 0.174 and 1.74x10-5 M for DCNQ and BROM, 
respectively. These low values confirmed the good sensitivity of the initial rate method and consequently its capability to 
determine low amounts of OMZ.  
3.7.1.2. Fixed time method 
In this method, the absorbance of the reaction solutions containing varying amounts of OMZ was measured at a 
pre-selected fixed time. Calibration plots of absorbances versus the concentrations of OMZ were established at fixed 
periods of time for the reactions (Table 4). The regression equations, correlation coefficients, and the limits of detection 
and quantification are given in Table 4.  
Table 4: Analytical parameters for the fixed time method of the proposed kinetic methods for 
determination of OMZ 
Method 
 
Time 
(min) 
Range 
g ml-1) 
R 
 
Slope  
(b) ± SD 
Intercept  
(a) ± SD 
LOD 
g ml-1) 
LOQ 
g ml-
1) 
DCNQ 5 30.0 -280 0.9988 0.0030 ± 0.0001 0.0105 ± 0.0029 3.27 9.92 
 10 20.0 -150 0.9996 0.0056 ± 0.0011 0.0029 ± 0.0030 1.79 5.43 
 20 10.0 - 90 0.9997 0.0104 ± 0.0006 -0.0081 ± 0.0047 1.50 4.55 
 30 6.0 - 60 0.9996 0.0141 ± 0.0007 -0.0029 ± 0.0025 0.58 1.76 
 40 5.0 - 50 0.9997 0.0158 ± 0.0005 0.0031 ± 0.0027 0.56 1.69 
BROM 5 50.0 -600 0.9985 0.0017 ± 0.0001 0.0118 ± 0.0083 16.06 48.67 
 10 30.0 -300 0.9996 0.0030 ± 0.0003 0.0127 ± 0.0069 7.45 22.57 
 15 25.0 - 275 0.9970 0.0034 ± 0.0005 0.0184 ± 0.0079 7.76 23.51 
 20 25.0 - 250 0.9997 0.0037 ± 0.0006 0.0108 ± 0.0077 6.9 20.91 
 25 20.0 -225 0.9998 0.0039 ± 0.0004 0.0135±0.0072 6.21 18.82 
 
The lowest limits of detection and quantification were obtained with fixed times of 40 and 25 min, for DCNQ and 
BROM, respectively.  However, the fixed times of 10 min showed wider concentration range for quantification. According 
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to the ICH guidelines for validation of analytical procedures [34], the detection limit is not required to be part of the 
validation. Therefore, based on wider concentration range and less time of analysis, the reaction time of 10 min was 
recommended for DCNQ and BROM for the determination of OMZ by the fixed time method, if the sensitivity is not 
required.  
3.7.2. Accuracy and precision 
The accuracy and precision of the proposed kinetic spectrophotometric methods were determined [43] at three 
concentration levels of OMZ by analyzing five replicate samples of each concentration by both the initial rate and fixed 
time methods. The relative standard deviations (RSD) for the results did not exceed 2.04 % (Table 5), proving the high 
reproducibility of the results and the precision of the method. This good level of precision was suitable for quality control 
analysis of OMZ in its pharmaceutical tablets.  
Table 5: Evaluation of the accuracy and precision of the initial rate and fixed time methods of the 
proposed methods for determination of OMZ 
Method 
 
Amount taken 
    (g ml-1) 
Recovery (%  RSD) a 
Initial rate method  Fixed time method 
DCNQ 5 101.5  1.90  101.1  1.85 
 25 99.5  1.85  98.5  0.68 
 50 99.6  0.96  99.2  0.45 
 
BROM 25 100.1  1.97  100.6  2.04 
 100 98.9  1.02  99.9  1.65 
 200 101.1  1.25  101.3  1.12 
 
a Recovery was calculated as the amount found / amount taken 100. Values are mean  RSD for five determinations. 
3.7.3. Specificity and interference 
 The proposed kinetic methods have the advantage of that all measurements in both DCNQ and BROM methods are 
performed in the visible region, away from the UV-absorbing interfering substances that might be co-extracted from OMZ-
containing dosage forms. Potential interferences by the excipients in the dosage forms were studied. Samples were 
prepared by mixing known amount (20 mg) of OMZ with various amounts of the common excipients such as starch, 
glucose, lactose, acacia, and magnesium stearate. The results (Table 6) showed that no interference was observed from 
any of these excipients with the proposed methods.  
Table 6: Analysis of OMZ in presence of common excipients by the proposed fixed-time method 
Ingredient Recovery (%  SD) a 
DCNQ BROM 
Starch (50)b 99.77  0.98 98.95  1.75 
Glucose (10) 99.12  1.15 98.59  1.87 
Lactose (10) 98.45  0.58 99.71  1.42 
Acacia (10) 100.07  0.97 97.96  0.85 
MSc (10) 99.63  1.13 99.02  1.21 
Average  SD 99.41  0.64 98.85  0.64 
Pool SD   0.96   1.42 
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a Values are mean of three determinations. 
b Figures in parenthesis are the amounts in mg added per 20 mg of OMZ.  
   c MS = Magnesium stearate. 
3.7.4. Ruggedness and robustness 
The ruggedness of the proposed methods was assessed by applying the procedures using two different instruments 
in two different laboratories at different elapsed time. Results obtained from lab-to-lab and day-to-day variation was found 
to be reproducible, as RSD did not exceed 3%. Robustness of the procedures was assessed by evaluating the influence 
of small variation of experimental variables [44], e.g. concentrations of acceptor reagents on the analytical performance of 
the proposed methods. In these experiments, one experimental parameter was changed while the other parameters were 
kept unchanged, and the recovery percentage was calculated each time. The small variations in any of the variables did 
not significantly affect the results; recovery percentages were 97.3 – 102.1%  1.62 - 2.37.  This provided an indication for 
the reliability of the proposed methods during routine work.  
3.8. Application of the proposed methods to the analysis of pharmaceutical tablets 
Depending on the obtained validation results, the proposed procedures were found to be suitable for the routine 
quality control analysis of OMZ. The proposed and the reported methods [25] were applied to the determination of OMZ in 
its dosage forms. The results obtained by the proposed methods were statistically compared with those obtained by the 
reported method. The recovery of the labeled amount was 98.6 – 100.5  0.88 -1.57% (Table 7).  
Table 7: Analysis of OMZ in its dosage forms by the proposed kinetic spectrophotometric methods 
Dosage form  Label claim (%  SD) a 
DCNQ Bromanil Reported c 
1. Gastrazole capsules Initial rate method 
 Recovery (%  SD) 99.1  1.09 99.5  0.88 100.4  1.34 
 t-valueb 1.68 1.26  
 F-valueb 1.51 2.32  
 Fixed-time method 
 Recovery (%  SD) 99.6  1.45 100.6  1.17  
 t-valueb 0.91 0.25  
 F-valueb 0.85 1.31  
2. Losec tablets Initial rate method 
 Recovery (%  SD) 98.7  1.35 98.6  1.57 100.9  1.18 
 t-valueb 2.74 2.61  
 F-valueb 1.31 1.77  
  Fixed-time method 
 Recovery (%  SD) 100.5  1.35 99.1  1.07  
 t-valueb 0.12 1.7  
 F-valueb 0.76 1.22  
a Values are mean of five determinations.   
b The tabulated values of t and F at 95% confidence limit are 2.78 and 6.39, respectively. 
c Reference 25.  
The results of t- and F-tests revealed that no significant differences were found between the proposed and reported 
methods at 95% confidence level with respect to precision and accuracy proving that all the proposed methods are 
applicable to the analysis of OMZ with comparable analytical performance.  
4. Conclusions 
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The charge-transfer complexes of OMZ with both π-acceptors BROM and DCNQ have been investigated by UV-VIS 
spectrophotometry, conductimetry, and by computational molecular modeling. A suggested mechanism for these CT 
reactions based on the spectroscopic study was postulated. The obtained colored complexes were utilized in the 
development of simple and accurate kinetic spectrophotometric methods for the analysis of OMZ in QCLs. The described 
methods was fully validated according to ICH guidelines. The proposed methods are superior to the previously reported 
spectrophotometric methods, because of many advantages:    
1. It used new (BROM and DCNQ) π-acceptors for determination of OMZ.  
2. The present method used 96-microwell plate as a reaction vessel and the ELISA reader to increase the automation 
and the high-throughput of the proposed methods to suit for the analysis of OMZ in QCLs.  
3. The use of micro-well plates provides a safer and economic tool for determination of OMZ contents in pharmaceutical 
dosage forms through decreasing the analysis cost and the risk of human exposure to toxic solvents.  
4. The proposed method is superior to the previously reported spectrophotometric methods for determination of OMZ in 
the terms of safety, improved selectivity, and high-throughput property. 
5. The use of both kinetic and automated methodology has overcome the  short stability time of the signal (only 15 min) 
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